Cameron Santoro

An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.

Multigene assays allow for patients to receive personalized breast cancer treatment by identifying promising therapeutic targets, which could improve patient clinical outcomes in the long term and help providers better understand tumor biology.

Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.

Sisters of women with high breast cancer risk share similar risk factors, including high polygenic scores, benign breast disease history, and denser breast tissue.

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.

Swedish women with prior false-positive mammograms, particularly those aged 60 to 75 with prior biopsies and low density, show elevated breast cancer risk, necessitating closer monitoring and better screening.

New research explores T cells and their signaling pathways in alopecia areata (AA), highlighting promising drug targets for future treatment.

Non-Caucasian patients with breast cancer face common influences in surgical decision-making due to fear, misinformation, cultural factors, and power dynamics, highlighting the need for patient-centered surgical decision-making.

Research suggests moderate to vigorous physical activity may help improve cognitive function in breast cancer survivors who have undergone chemotherapy and developed cancer-related cognitive impairment (CRCI).

Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.

Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.

Topical treatments and minoxidil solutions were found to be the most effective, safe, and affordable first-line options for treating pediatric AA.

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

Registered dietitian, Molly Kimball, RD, CSSD, of Ochsner Health, navigates cultural identity in diet changes for long-term success, in an interview.

A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.

Black women with alopecia often struggle between concealing their hair loss and protecting their fragile scalps, all while seeking to express their cultural identity and build self-confidence.

Molly Kimball, RD, CSSD, of Ochsner Health, advocates for sustainable changes to populations' everyday behaviors to make healthy choices easier and more culturally relevant.

A US study found alopecia areata (AA) is more common in non-White patients, likely due to underrepresentation in dermatology, leading to less consideration of AA as a diagnosis for non-White individuals.

Sidney (Beau) Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, believes that the health care system should focus on preventing illness and disease, rather than just treating them after they occur.

People with alopecia areata who experience hair regrowth may also see improvements in their quality of life and mental health, according to a new study.

The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo.

Human activity is driving climate change, unleashing a cascade of physical and mental hardships on vulnerable populations.

The top 5 most-read dermatology content of 2023 included topics in melanoma, acne scarring, hidradenitis suppurativa, chronic kidney disease, hyperhidrosis, and infertility rates.

A study found Hispanic people in Tampa, Florida and Ponce, Puerto Rico are prone to sunburns but lack sun safety habits, putting them at higher risk for skin cancer.

The top 5 most-read articles on sleep published on AJMC.com this year include content focusing on narcolepsy management, approval of medication to treat insomnia, and the association of metabolic syndrome with sleep duration.

The top 5 most-read population health articles of 2023 included nicotine consumption, the future of health care initiatives, medical insurance, and the results of low-sodium diets.

Join Shiela Plasencia, director of practice support, Community Oncology Alliance (COA) as she explores improving health treatments for marginalized communities and how to apply it to the oncology population.

Peter Katzmarzyk discusses contributing factors to obesity and the chronic disease preventions and implementations collaborative care teams like nutritionists, psychologists, and physical therapists should support.